HRP20201274T1 - Novi fosfotriazoli mrna s analognom cap-a na kraju 5', pripravci koji ih sadržavaju, rna molekule koje ih uključuju u svojem sastavu, njihova upotreba i postupak sinteze rna molekule, proteina ili peptida - Google Patents
Novi fosfotriazoli mrna s analognom cap-a na kraju 5', pripravci koji ih sadržavaju, rna molekule koje ih uključuju u svojem sastavu, njihova upotreba i postupak sinteze rna molekule, proteina ili peptida Download PDFInfo
- Publication number
- HRP20201274T1 HRP20201274T1 HRP20201274TT HRP20201274T HRP20201274T1 HR P20201274 T1 HRP20201274 T1 HR P20201274T1 HR P20201274T T HRP20201274T T HR P20201274TT HR P20201274 T HRP20201274 T HR P20201274T HR P20201274 T1 HRP20201274 T1 HR P20201274T1
- Authority
- HR
- Croatia
- Prior art keywords
- rna molecule
- accordance
- group
- compound
- same
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 6
- 108090000623 proteins and genes Proteins 0.000 title claims 6
- 102000004169 proteins and genes Human genes 0.000 title claims 6
- 230000002194 synthesizing effect Effects 0.000 title claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 title 2
- KKMDYQUDLZESGL-UHFFFAOYSA-N O=P(=O)C1=CNN=N1 Chemical compound O=P(=O)C1=CNN=N1 KKMDYQUDLZESGL-UHFFFAOYSA-N 0.000 title 1
- 108020004999 messenger RNA Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 10
- 108700026244 Open Reading Frames Proteins 0.000 claims 5
- 230000014616 translation Effects 0.000 claims 5
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 238000003786 synthesis reaction Methods 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 2
- 210000004748 cultured cell Anatomy 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 238000001243 protein synthesis Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Claims (11)
1. Spoj formule (I)
[image]
ili njegov stereoizomer ili sol,
naznačen time, da su R1 i R2 odabrani iz skupine koja se sastoji od N, N+-CH3, N+-C2H5, N+-C3H8, N+-C4H5, N+-CH2C6H5 pri čemu barem jedan od R1, R2 nije N.
n i m neovisno su odabrani iz skupine koja se sastoji od 0, 1 i 2;
X je odabran iz skupine koja se sastoji od O, NH, S, CH2
k je 1 ili 2
Y je ili odsutan ili je odabran iz skupine -CH2-, -CH2CH2-, -CH2O-, -CH2S-, -CH2NH- , -CH2CH2O-, -CH2CH2NH-, -CH2CH2S
R3, R4, R5, R6 su odabrani iz skupine koja se sastoji od H, OH, OCH3 ili OCH2CH3; pri čemu R3 i R4 mogu biti isti ili različiti; R5 i R6 mogu biti isti ili različiti; ako je bilo koji od R3, R4 različit od OH tada su R5 i R6 oba OH; ako je bilo koji od R5i R6 različit od OH, tada su R3 i R4 su oba OH.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da R1 N+, -CH3, R3 i R4 su odabrani iz skupine koja se sastoji od OH i OCH3, a najmanje jedan od R3, R4 nije OH, R5 i R6 su OH, i n je najmanje 1.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da su R2 N+-CH3, R5 i R6 odabrani iz skupine koja se sastoji od OH i OCH3, a najmanje jedan od R5, R6 nije OH, R3 i R4 su oba OH, i m je najmanje 1.
4. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj odabran iz skupine koja sadržava sljedeće:
[image]
[image]
[image]
5. Pripravak, naznačen time, da sadržava barem jedan od spojeva kako je definirano u bilo kojem od patentnih zahtjeva 1 do 4 ili barem jedan njegov stereoizomer ili sol i pogodan nosač ili razrjeđivač.
6. Molekula RNA, naznačena time, da njezin kraj 5', uključuje spoj kako je definirano u skladu s bilo kojim od patentnih zahtjeva 1 do 4.
7. Postupak sinteze in vitro molekule RNA kako je definirano u skladu s patentnim zahtjevom 6, naznačen time, da navedeni postupak uključuje reakciju ATP, CTP, UTP i GTP, spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 4 ili pripravka u skladu s patentnim zahtjevom 5, i polinukleotidnog predložka u prisutnosti RNA polimeraze, u uvjetima koji omogućuju transkripciju RNA polimeraze polinukleotidnog predloška u kopiju RNA; pri čemu će neke od kopija RNA sadržavati spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 4, za dobivanje molekule RNA kako je definirano u skladu s patentnim zahtjevom 6.
8. Postupak sinteze proteina ili peptida in vitro, naznačen time, da navedeni postupak uključuje prevođenje molekule RNA kako je definirano u skladu s patentnim zahtjevom 6, u sustav za sintezu proteina bez ćelija, pri čemu molekula RNA sadržava otvoreni okvir čitanja, u uvjetima koji omogućuju translaciju otvorenog okvira čitanja molekule RNA u protein ili peptid kodiran otvorenim okvirom za čitanje.
9. Postupak sinteze proteina ili peptida u kultiviranim stanicama, naznačen time, da navedeni postupak sadržava translaciju molekule RNA kako je definirano u skladu s patentnim zahtjevom 6 u kultiviranim stanicama, pri čemu RNA molekula sadržava otvoreni okvir čitanja, pod uvjetima koji omogućuju prevođenje otvorenog okvira čitanja molekule RNA u protein ili peptid kodiran navedenim otvorenim okvirom za čitanje.
10. Uporaba spoja kako je definirano u skladu s bilo kojim od patentnih zahtjeva 1 do 4, ili pripravka kako je definirano u skladu s patentnim zahtjevom 5, naznačena time, da se koristi u in vitro sintezi RNA molekule.
11. Uporaba molekule RNA kako je definirano u skladu s patentnim zahtjevom 6, naznačena time, da se koristi u in vitro sintezi proteina ili peptida.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL417980A PL417980A1 (pl) | 2016-07-16 | 2016-07-16 | Nowe fosfotriazolowe analogi kapu końca 5' mRNA, kompozycja je zawierająca, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA, białka i peptydu |
| PCT/IB2017/054221 WO2018015845A1 (en) | 2016-07-16 | 2017-07-12 | Novel phosphotriazole mrna 5'-end cap analogs, composition comprising the same, rna molecule incorporating the same, uses thereof and method of synthesizing rna molecule, protein or peptide |
| EP17754482.2A EP3484907B1 (en) | 2016-07-16 | 2017-07-12 | Novel phosphotriazole mrna 5'-end cap analogs, composition comprising the same, rna molecule incorporating the same, uses thereof and method of synthesizing rna molecule, protein or peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201274T1 true HRP20201274T1 (hr) | 2020-12-11 |
Family
ID=59656110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201274TT HRP20201274T1 (hr) | 2016-07-16 | 2020-08-13 | Novi fosfotriazoli mrna s analognom cap-a na kraju 5', pripravci koji ih sadržavaju, rna molekule koje ih uključuju u svojem sastavu, njihova upotreba i postupak sinteze rna molekule, proteina ili peptida |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10696709B2 (hr) |
| EP (1) | EP3484907B1 (hr) |
| CY (1) | CY1123516T1 (hr) |
| DK (1) | DK3484907T3 (hr) |
| ES (1) | ES2820242T3 (hr) |
| HR (1) | HRP20201274T1 (hr) |
| HU (1) | HUE051312T2 (hr) |
| LT (1) | LT3484907T (hr) |
| PL (2) | PL417980A1 (hr) |
| PT (1) | PT3484907T (hr) |
| RS (1) | RS60848B1 (hr) |
| SI (1) | SI3484907T1 (hr) |
| WO (1) | WO2018015845A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023250528A1 (en) * | 2022-06-24 | 2023-12-28 | The Broad Institute, Inc. | Compositions and methods for preparing capped circular rna molecules |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8969545B2 (en) | 2011-10-18 | 2015-03-03 | Life Technologies Corporation | Alkynyl-derivatized cap analogs, preparation and uses thereof |
-
2016
- 2016-07-16 PL PL417980A patent/PL417980A1/pl unknown
-
2017
- 2017-07-12 LT LTEP17754482.2T patent/LT3484907T/lt unknown
- 2017-07-12 PT PT177544822T patent/PT3484907T/pt unknown
- 2017-07-12 PL PL17754482T patent/PL3484907T3/pl unknown
- 2017-07-12 ES ES17754482T patent/ES2820242T3/es active Active
- 2017-07-12 WO PCT/IB2017/054221 patent/WO2018015845A1/en unknown
- 2017-07-12 DK DK17754482.2T patent/DK3484907T3/da active
- 2017-07-12 US US16/318,126 patent/US10696709B2/en active Active
- 2017-07-12 HU HUE17754482A patent/HUE051312T2/hu unknown
- 2017-07-12 SI SI201730371T patent/SI3484907T1/sl unknown
- 2017-07-12 RS RS20200968A patent/RS60848B1/sr unknown
- 2017-07-12 EP EP17754482.2A patent/EP3484907B1/en active Active
-
2020
- 2020-08-13 CY CY20201100762T patent/CY1123516T1/el unknown
- 2020-08-13 HR HRP20201274TT patent/HRP20201274T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL417980A1 (pl) | 2018-01-29 |
| LT3484907T (lt) | 2020-09-10 |
| PT3484907T (pt) | 2020-09-17 |
| RS60848B1 (sr) | 2020-10-30 |
| US20200055891A1 (en) | 2020-02-20 |
| EP3484907B1 (en) | 2020-05-13 |
| HUE051312T2 (hu) | 2021-03-01 |
| PL3484907T3 (pl) | 2021-02-08 |
| SI3484907T1 (sl) | 2020-12-31 |
| DK3484907T3 (da) | 2020-08-17 |
| ES2820242T3 (es) | 2021-04-20 |
| EP3484907A1 (en) | 2019-05-22 |
| WO2018015845A1 (en) | 2018-01-25 |
| US10696709B2 (en) | 2020-06-30 |
| CY1123516T1 (el) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140771T1 (hr) | Sinteza i uporaba anti-reverznih analoga fosfortioata na cap glasniäśke rna | |
| RU2016120012A (ru) | Ингибиторы рецептора фактора роста фибробластов | |
| HRP20110045T1 (hr) | Sinteza acilaminoalkenilen amida korisnih kao antagonista supstance p | |
| RU2016136530A (ru) | Композиции селеноорганических соединений и способы их применения | |
| CN103613717B (zh) | 一种自乳化型丙烯酸有机硅蜡防护材料及制备方法与应用 | |
| DE602006019499D1 (de) | Eine pentakis(dimethylamino)disilanvorstufe enthaltende verbindung, und verfahren zu deren herstellung | |
| HRP20201274T1 (hr) | Novi fosfotriazoli mrna s analognom cap-a na kraju 5', pripravci koji ih sadržavaju, rna molekule koje ih uključuju u svojem sastavu, njihova upotreba i postupak sinteze rna molekule, proteina ili peptida | |
| BR0311693A (pt) | Sal de formato de o-desmetil-venlafaxina | |
| CN111433188A (zh) | 一种用于抗体药物偶联物的连接子及其应用 | |
| DE50311220D1 (de) | Verfahren zur herstellung von hochreinem methyl-tert.-butylether | |
| NZ336011A (en) | Process for producing beta-hydroxyalkylamides and their use as cross-linkers in surface coatings | |
| RU2015144172A (ru) | Композиции клеточных культур с антиоксидантами и способы получения полипептидов | |
| TW201909890A (zh) | 培養基添加用組成物及培養基添加用化合物以及使用此等之細胞或組織的培養方法 | |
| CN110387009A (zh) | 一种两性聚合物表面活性剂、及含有该表面活性剂的无铬鞣皮革加脂剂 | |
| CN102356085A (zh) | 具有脯氨酸环结构的咪唑并噻唑衍生物 | |
| EP2184342A3 (en) | Oil containing starch granules for delivering benefit-additives to a substrate | |
| BR112017006645A2 (pt) | redução de água de baixa a média gama com o uso de polímeros de policarboxilato em pente | |
| DK0910575T3 (da) | Fremgangsmåde til fremstilling af peptider | |
| AU2009283000B2 (en) | Processes for producing N-alkyl (alkyl)acrylamides | |
| DE602004026500D1 (de) | Verfahren zur Markierung phosphorylierten Peptiden, Komplexverbindunger, Verfahren zu deren Herstellung und Zwischenprodukte | |
| PE20090824A1 (es) | Proceso para la preparacion de trifluoralquil-fenil sulfonamidas y de sulfonamidas heterociclicas | |
| ATE414126T1 (de) | Metallpigmentzusammensetzung | |
| FR2764282A1 (fr) | Compose a base de titane, de cerium et d'alcalin ou d'alcalino-terreux, ses procedes de preparation et son utilisation comme pigment colorant | |
| JP6153379B2 (ja) | 細胞凝集塊形成能を有するペプチド | |
| Gadekar et al. | Reductive removal of methoxyacetyl protective group using sodium borohydride |